EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial

Matthew P Gilbert iD, Joan Skelly, Adrian F Hernandez, Jennifer B Green, Konstantin A Krychtiuk, Christopher B Granger, Lawrence A Leiter, John J V McMurray iD, Stefano Del Prato, Richard E Pratley

Diabetes, Obesity and Metabolism · 2024-05 · 26 (5) · 1714-1722

DOI: 10.1111/dom.15479 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 06.02.2024. Verfasst von Matthew P Gilbert und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Endocrinology, Diabetes, and Osteoporosis, Larner College of Medicine at The University of Vermont, Burlington, V…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Cardiovascular Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim To analyse the effects of albiglutide, a glucagon‐like peptide 1 receptor agonist, on cardiovascular outcomes in older adults aged ≥65 years with type 2 diabetes and cardiovascular disease who participated in the Harmony Outcomes trial (NCT02465515). Materials and methods We conducted a post hoc analysis of the primary endpoint of the Harmony Outcomes trial—time to first occurrence of a major adverse cardiovascular event—in subgroups of participants aged

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Cardiovascular DiseasesHumansAgedHypoglycemic AgentsTreatment OutcomeGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor

Stichwörter der Autor:innen

cardiovascular diseaseelderlyglucagon‐like peptide 1 analoguerandomized trialtype 2 diabetes

Substanzen

rGLP-1 proteinHypoglycemic AgentsGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor

Autor:innen und Institutionen

  • Department of Medicine, Division of Endocrinology, Diabetes, and Osteoporosis, Larner College of Medicine at The University of Vermont, Burlington, Vermont, USA.
  • Department of Biomedical Statistics, The University of Vermont, Burlington, Vermont, USA.
  • Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
  • Department of Medicine, Division of Endocrinology, Duke University School of Medicine, Durham, North Carolina, USA.
  • Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
  • School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland.

ORCID-Profile: Matthew P Gilbert, John J V McMurray

Zitieren

APA

Gilbert, M. P., Skelly, J., Hernandez, A. F., Green, J. B., Krychtiuk, K. A., Granger, C. B., Leiter, L. A., McMurray, J. J. V., Del Prato, S., & Pratley, R. E. (2024). Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial. Diabetes, Obesity and Metabolism, 26(5), 1714-1722. https://doi.org/10.1111/dom.15479

Vancouver

Gilbert MP, Skelly J, Hernandez AF, Green JB, Krychtiuk KA, Granger CB, et al. Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial. Diabetes, Obesity and Metabolism. 2024;26(5):1714-1722. doi:10.1111/dom.15479

BibTeX
@article{Gilbert2024,
  author = {Gilbert, Matthew P and Skelly, Joan and Hernandez, Adrian F and Green, Jennifer B and Krychtiuk, Konstantin A and Granger, Christopher B and Leiter, Lawrence A and McMurray, John J V and Del Prato, Stefano and Pratley, Richard E},
  title = {Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  volume = {26},
  number = {5},
  pages = {1714--1722},
  doi = {10.1111/dom.15479}
}
Kostenlos starten →